Analysis of a registry database for esophageal cancer from high-volume centers in China
- PMID: 31863099
- DOI: 10.1093/dote/doz091
Analysis of a registry database for esophageal cancer from high-volume centers in China
Abstract
Esophageal cancer has a high incidence among malignancies in China, but a comprehensive picture of the status of its surgical management in China has hitherto not been available. A nationwide database has recently been established to address this issue.
Method: A National Database was setup through a network platform, and data was collected from 70 high-volume centers (>100 esophagectomies/per year) across China. Data was entered between January 2009 and December 2014, and was analyzed in June 2015 after a minimal follow-up of 6 months for all patients. 8181 patients with complete data who received surgery for primary esophageal cancer on the Database were included in the analysis.
Result: In this series, there were 6052 males and 2129 females, with a mean age of 60.5 years (range: 22-90 years). The pathology in 95.5% of patients was squamous cell carcinoma. The pathological stage distribution was 1.2% in stage 0, 2.5% in Ia, 11.5% in Ib, 14.8% in IIa, 36.1% in IIb, 19.3% in IIIa, 8.3% in IIIb, 6.2% in IIIc. 1800 patients (22.0%) with locally advanced disease received preoperative neoadjuvant therapy and 3592 patients (43.9%) underwent postoperative adjuvant chemotherapy and/or radiotherapy. The esophagectomies were performed through left thoracotomy approach in 5870 cases (72.6%), through right chest approach in 2215 cases (27.4%) including right thoracotomy (21.3%) and VATS (6.1%). The 30-day postoperative mortality rate was 0.6% (43 patients), and the overall postoperative complication rate was 11.6% (951 patients). The 1-, 3-, and 5-year overall survival rates were 82.6%, 61.6%, and 52.9%, respectively.
Conclusion: This National Registry Database from high-volume centers provides a comprehensive picture of surgical management for esophageal cancer in China for the first time. Squamous cell carcinoma predominates, but there is heterogeneity with respect to the surgical approach and perioperative oncologic management. Overall, surgical mortality and morbidity rates are low, and good survival rates have been achieved due to improvement of surgical treatment technology in recent years.
Keywords: esophageal cancer; outcomes; surgery; survival.
© The Author(s) 2019. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
[Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database].Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):228-233. doi: 10.3760/cma.j.cn112152-20191112-00729. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32252202 Chinese.
-
Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.World J Gastroenterol. 2014 Dec 28;20(48):18397-403. doi: 10.3748/wjg.v20.i48.18397. World J Gastroenterol. 2014. PMID: 25561808 Free PMC article.
-
Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.Cancer. 2017 Jun 1;123(11):2043-2053. doi: 10.1002/cncr.30565. Epub 2017 Feb 2. Cancer. 2017. PMID: 28152166
-
[New trends in neoadjuvant chemoradiotherapy for locally-advanced esophageal cancer: esophagectomy--is it necessary?].Gan To Kagaku Ryoho. 2000 Nov;27(13):2016-22. Gan To Kagaku Ryoho. 2000. PMID: 11103231 Review. Japanese.
-
Induction therapy does not increase surgical morbidity after esophagectomy for cancer.Ann Thorac Surg. 2004 Nov;78(5):1783-9. doi: 10.1016/j.athoracsur.2004.04.081. Ann Thorac Surg. 2004. PMID: 15511475 Review.
Cited by
-
The implementation status of prehabilitation during neoadjuvant chemotherapy for patients with locally advanced esophageal cancer: a questionnaire survey to the board-certified facilities in Japan.Esophagus. 2024 Oct;21(4):496-504. doi: 10.1007/s10388-024-01075-7. Epub 2024 Jul 24. Esophagus. 2024. PMID: 39048749
-
Comprehensive risk score of the E-PASS scoring system serves a prognostic indicator for patients after neoadjuvant therapy and curative esophageal cancer surgery: a multicenter retrospective study.Front Oncol. 2025 Jun 6;15:1617683. doi: 10.3389/fonc.2025.1617683. eCollection 2025. Front Oncol. 2025. PMID: 40584452 Free PMC article.
-
Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression.Cancer Immunol Immunother. 2023 Dec;72(12):4249-4259. doi: 10.1007/s00262-023-03561-w. Epub 2023 Nov 9. Cancer Immunol Immunother. 2023. PMID: 37943341 Free PMC article.
-
Deep Learning for Automated Contouring of Gross Tumor Volumes in Esophageal Cancer.Front Oncol. 2022 Jul 18;12:892171. doi: 10.3389/fonc.2022.892171. eCollection 2022. Front Oncol. 2022. PMID: 35924169 Free PMC article.
-
Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes.Ann Transl Med. 2021 Oct;9(20):1576. doi: 10.21037/atm-21-4756. Ann Transl Med. 2021. PMID: 34790782 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical